E. Ohman J or Asset Management AB Takes Position in Teva Pharmaceutical Industries Ltd. $TEVA

E. Ohman J or Asset Management AB purchased a new position in shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 19,680 shares of the company’s stock, valued at approximately $614,000.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the stock. 180 Wealth Advisors LLC bought a new position in Teva Pharmaceutical Industries during the 4th quarter worth $260,000. Wealth Enhancement Advisory Services LLC lifted its stake in Teva Pharmaceutical Industries by 3.3% in the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 11,911 shares of the company’s stock valued at $382,000 after buying an additional 379 shares during the last quarter. Grove Bank & Trust boosted its holdings in shares of Teva Pharmaceutical Industries by 300.0% during the fourth quarter. Grove Bank & Trust now owns 1,000 shares of the company’s stock valued at $31,000 after acquiring an additional 750 shares during the period. Magnus Financial Group LLC grew its position in shares of Teva Pharmaceutical Industries by 27.8% during the fourth quarter. Magnus Financial Group LLC now owns 37,874 shares of the company’s stock worth $1,182,000 after acquiring an additional 8,235 shares during the last quarter. Finally, Union Bancaire Privee UBP SA grew its position in shares of Teva Pharmaceutical Industries by 3,831.4% during the fourth quarter. Union Bancaire Privee UBP SA now owns 786,272 shares of the company’s stock worth $23,733,000 after acquiring an additional 766,272 shares during the last quarter. Institutional investors and hedge funds own 54.05% of the company’s stock.

Insider Activity at Teva Pharmaceutical Industries

In other news, EVP Richard Daniell sold 17,295 shares of the company’s stock in a transaction on Thursday, March 5th. The stock was sold at an average price of $31.67, for a total transaction of $547,732.65. Following the completion of the sale, the executive vice president directly owned 85,755 shares of the company’s stock, valued at $2,715,860.85. This represents a 16.78% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Placid Jover sold 14,150 shares of the business’s stock in a transaction dated Thursday, March 5th. The stock was sold at an average price of $31.67, for a total value of $448,130.50. Following the sale, the insider owned 6,774 shares in the company, valued at approximately $214,532.58. The trade was a 67.63% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 920,901 shares of company stock valued at $30,056,789 over the last ninety days. Company insiders own 0.49% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages recently weighed in on TEVA. Bank of America lifted their price objective on shares of Teva Pharmaceutical Industries from $29.00 to $32.00 and gave the company a “buy” rating in a research report on Tuesday, December 9th. Scotiabank upped their target price on shares of Teva Pharmaceutical Industries from $35.00 to $40.00 and gave the stock a “sector outperform” rating in a research report on Thursday, January 29th. Truist Financial raised their price target on shares of Teva Pharmaceutical Industries from $38.00 to $42.00 and gave the company a “buy” rating in a research note on Wednesday, February 18th. Jefferies Financial Group lifted their price target on Teva Pharmaceutical Industries from $29.00 to $40.00 and gave the company a “buy” rating in a report on Tuesday, January 6th. Finally, Piper Sandler reiterated an “overweight” rating and set a $41.00 price objective (up from $40.00) on shares of Teva Pharmaceutical Industries in a research report on Wednesday, March 4th. One analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $37.67.

Teva Pharmaceutical Industries Price Performance

Shares of Teva Pharmaceutical Industries stock opened at $29.44 on Thursday. Teva Pharmaceutical Industries Ltd. has a 52 week low of $12.47 and a 52 week high of $37.35. The company has a current ratio of 1.04, a quick ratio of 0.80 and a debt-to-equity ratio of 1.89. The stock has a market cap of $33.85 billion, a PE ratio of 24.53, a price-to-earnings-growth ratio of 9.75 and a beta of 0.72. The company’s 50-day moving average price is $32.45 and its two-hundred day moving average price is $27.28.

Teva Pharmaceutical Industries (NYSE:TEVA) last posted its quarterly earnings data on Wednesday, January 28th. The company reported $0.96 earnings per share for the quarter, beating the consensus estimate of $0.65 by $0.31. Teva Pharmaceutical Industries had a net margin of 8.16% and a return on equity of 46.28%. The company had revenue of $4.71 billion during the quarter, compared to analyst estimates of $4.36 billion. During the same quarter last year, the firm posted $0.71 EPS. The business’s revenue for the quarter was up 11.4% on a year-over-year basis. Teva Pharmaceutical Industries has set its FY 2026 guidance at 2.570-2.770 EPS. As a group, sell-side analysts anticipate that Teva Pharmaceutical Industries Ltd. will post 2.5 EPS for the current fiscal year.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.